A Review of NHS co-designed COPD Digital Support: Lenus COPD

ByDr. Mega Boo Boo
RECEIVER Trial — Digital COPD Support — GIVEMEA Study Guide
GIVEMEA Study Guide · Digital Health Interventions

Long-Term Usage and Improved Clinical Outcomes with Adoption of a COPD Digital Support Service

Taylor A, Cushing A, Dow M, et al. · Int J Chron Obstruct Pulmon Dis 18:1301–1318 · 2023

Observational Cohort Implementation-Effectiveness n=83 + 415 matched controls Sep 2019 – Aug 2021
83Participants
77%Sustained Users
335dMed. Time to Event
8.12dMean OBD Reduction
78wksMean Follow-up
Central Finding
The RECEIVER trial demonstrated sustained high utilization of a co-designed COPD digital support service among patients with severe COPD, with 77% maintaining regular use for over one year. Participants showed improved survival metrics and reduced hospitalization burden compared to matched controls, despite the progressive nature of COPD.

Research Question

Would people with severe COPD continue to utilize a co-designed patient web application throughout long-term follow-up, and what impact would adoption of this digital service have on clinical outcomes when integrated alongside routine care?

Study Context

While digital self-management tools for COPD show promise, evidence of sustained engagement and significant clinical benefits remains limited. The RECEIVER trial aimed to address these gaps by evaluating both long-term utilization patterns and clinical outcomes of the Lenus COPD digital support service in NHS Greater Glasgow & Clyde.

Primary Outcome

Utilization was determined by daily COPD Assessment Test (CAT) completion. High and sustained use was observed with 77% of participants completing at least one CAT entry per week on ≥50% of follow-up weeks. Mean weekly completion was 79.8% over the first year, with an average of 4.0 daily entries per participant across the study period.

Clinical Outcomes

Compared to 415 matched controls, RECEIVER participants showed longer median time to death or COPD/respiratory-related admission (335 days vs 155 days, p=0.047, HR 0.740). Mean reduction in annual occupied bed days was 8.12 days for RECEIVER participants versus 3.38 days for controls. Quality of life and symptom burden remained stable despite disease progression.

Equity Finding

Critically, utilization levels among participants residing in the most socioeconomically deprived areas (SIMD quintile 1) were equivalent to those in less deprived areas, demonstrating that well-designed digital tools can achieve equitable engagement across socioeconomic strata.

Key Survival and Admission Metrics

Outcome RECEIVER Control Significance
Median time to admission/death 335 days 155 days p=0.047
Median time to first admission 400 days 255 days p=0.241 (NS)
12-month mortality rate 16.9% 24.1% p=0.215 (NS)
Mean OBD reduction (annual) 8.12 days 3.38 days Effect size 0.535

■ Digital Health Concepts   ■ Study Design   ■ Outcome Measures   ■ Implementation Science

Digital Health Concepts

Patient Web Application
Tap to reveal
Patient Web Application
Smartphone/tablet/computer accessible interface where patients enter daily patient-reported outcomes (PROs), view self-management advice, and communicate asynchronously with clinicians. The Lenus COPD application prompted daily CAT entries and provided standardized educational resources.
Clinician Dashboard
Tap to reveal
Clinician Dashboard
Interface aggregating structured data from electronic health records, patient-reported outcomes, wearables, and home NIV machines. Used to support decision-making during routine and patient-initiated clinical contacts, not for continuous surveillance.
Digital Support Service
Tap to reveal
Digital Support Service
The complete Lenus COPD system comprising patient application, clinician dashboard, asynchronous messaging facility, and support website. Designed via patient-clinician co-design to integrate with rather than replace routine care workflows.
PRO (Patient-Reported Outcome)
Tap to reveal
PRO (Patient-Reported Outcome)
Health data reported directly by patients without clinician interpretation. In RECEIVER, PROs included daily CAT scores, weekly MRC Dyspnoea scores, and four-weekly EQ-5D VAS measurements, providing granular symptom trend data.

Study Design

Hybrid Implementation-Effectiveness Study
Tap to reveal
Hybrid Implementation-Effectiveness
Study design evaluating both clinical effectiveness (does the intervention work?) and implementation success (can it be deployed in real-world settings?) simultaneously. Allows for intervention adaptations during deployment while maintaining evaluation rigor.
Matched Control Cohort
Tap to reveal
Matched Control Cohort
415 individuals identified from NHS GG&C Safe Haven dataset, matched 5:1 to each RECEIVER participant on sex, age, admission timing (±7 days), and service non-use. Matching controlled for COVID-19 period effects on COPD outcomes.
Index Date
Tap to reveal
Index Date
Reference point for outcome analysis, set as each RECEIVER participant’s onboarding date. Matched controls shared this index date, ensuring temporal alignment for pre-post comparisons and survival analyses.
Data Censor Date
Tap to reveal
Data Censor Date
August 31, 2021 — the endpoint for all outcome measurements. Set to allow 12–24 months follow-up for all participants. Events after this date are not captured in the analysis.

Outcome Measures

CAT (COPD Assessment Test)
Tap to reveal
CAT (COPD Assessment Test)
Validated 8-item questionnaire measuring COPD symptom burden. Scores range 0–40 (higher = worse impact). Used daily in RECEIVER to track utilization and symptom trends. Baseline mean was 23.2 (high impact range).
Occupied Bed Days (OBD)
Tap to reveal
Occupied Bed Days (OBD)
Total hospital days per year for COPD/respiratory admissions. Key healthcare utilization metric capturing both admission frequency and length of stay. RECEIVER participants showed mean reduction of 8.12 days vs 3.38 days in controls.
EQ-5D VAS
Tap to reveal
EQ-5D VAS
EuroQol visual analogue scale measuring health-related quality of life on a 0–100 scale. Participants rated current health state four-weekly throughout the study. Despite COPD’s progressive nature, VAS scores remained stable across study period.
Community-Managed Exacerbation
Tap to reveal
Community-Managed Exacerbation
COPD worsening requiring treatment change (antibiotics/steroids) but managed without hospitalization. Median of 2 events per participant per year were self-reported through the application, with higher rates among most engaged users.

Implementation Science

Co-Design
Tap to reveal
Co-Design
Iterative development approach incorporating semi-structured interviews with people living with COPD and clinicians. Resulted in System Usability Scale score of 85/100 (above average). Ensured tools addressed real user needs and workflows.
SIMD (Scottish Index of Multiple Deprivation)
Tap to reveal
SIMD
Relative measure of socioeconomic deprivation across Scotland, divided into quintiles. 58% of RECEIVER participants and 63% of controls resided in quintile 1 (most deprived), reflecting typical COPD burden distribution. Utilization was equivalent across quintiles.
Sustained User
Tap to reveal
Sustained User
Participant completing at least one CAT entry per week on ≥50% of possible follow-up weeks. 77% of RECEIVER cohort (64/83) met this threshold. Notably, 24 of 39 participants who paused usage subsequently resumed engagement.
Safe Haven
Tap to reveal
Safe Haven
NHS GG&C secure de-identified dataset repository containing linked demographic, admission, and mortality data for all COPD patients in the health board. Source for control cohort identification and matching algorithm execution.

Study Design & Setting

Design

  • Prospective observational cohort with hybrid implementation-effectiveness framework
  • Registered prospectively (NCT04240353) with published protocol
  • Conducted according to UK Policy Framework for Health and Social Care Research
  • Recruitment: September 2019 – March 2020 (stopped due to COVID-19 lockdown)
  • Follow-up continued to data censor date: August 31, 2021
  • Mean follow-up: 78 weeks (range 12–24 months)

Setting

  • NHS Greater Glasgow & Clyde secondary care respiratory services
  • Urban Scottish population with high COPD burden in deprived communities
  • Integration with existing NHS electronic health record systems
  • Deployment during COVID-19 pandemic (March 2020 onwards)

Participants

RECEIVER Cohort Inclusion Criteria

  • Age ≥18 years at onboarding
  • Confirmed COPD diagnosis (GOLD 2019 criteria)
  • COPD exacerbation requiring hospitalization in previous 12 months AND/OR chronic hypercapnic respiratory failure/sleep-disordered breathing meeting criteria for home NIV/CPAP
  • Daily access to smartphone, tablet, or desktop computer with internet (personally or through close contact)

RECEIVER Cohort Exclusion Criteria

  • Lack of capacity to give informed consent
  • Communication barrier precluding service use

Control Cohort Matching Criteria

  • COPD or respiratory-related admission within 7 days prior to matched RECEIVER participant’s onboarding date
  • Alive at matched participant’s onboarding date
  • Same sex as matched participant
  • Not already matched to another RECEIVER participant (unique matching)
  • Not a user of the intervention (COPD digital service)
  • Five controls matched per RECEIVER participant (n=415 total)

Data Collection & Outcomes

Primary Outcome

  • Utilization measured by daily CAT entry completion through patient application
  • Sustained use defined as ≥1 CAT entry per week on ≥50% of follow-up weeks
  • Seven-day rolling average completion calculated for utilization quartile stratification

Clinical Secondary Outcomes

  • Survival metrics: time to first COPD/respiratory-related admission, time to death, time to admission or death (Kaplan-Meier analysis, log rank test)
  • Annual admissions: change in COPD/respiratory-related admission count and occupied bed days (pre-post index date comparison)
  • Quality of life: EQ-5D VAS trends across four time windows
  • Symptom burden: CAT score trends across four time windows
  • Community-managed exacerbations: participant-reported events in first year

Data Sources

  • Patient-reported outcomes: daily CAT, weekly MRC Dyspnoea scale, four-weekly EQ-5D VAS
  • Electronic health records: baseline demographics, physiology, medications, comorbidities, admission/discharge data
  • Home NIV machines: therapy adherence and summary data (ResMed Lumis 150 ST-A)
  • Wearables: activity data (Fitbit Charge 3) — not analyzed in this paper
  • Safe Haven dataset: control cohort identification and outcome data

Statistical Analysis

Analysis Approach

  • Utilization calculated from participants alive and onboarded at each timepoint
  • Survival analyses: Kaplan-Meier with log rank test, unadjusted hazard ratios with 95% CI
  • Admission changes: Wilcoxon signed-rank test effect sizes for RECEIVER vs control
  • Exploratory analyses: Kruskal-Wallis and chi-squared tests for baseline characteristics across utilization quartiles
  • Software: R version 4.0.5
  • Significance threshold: p<0.05
[1]

Lenferink A, Brusse-Keizer M, van der Valk PD, et al.

Cochrane Database Syst Rev 2017;8:CD011682
Systematic Review Self-Management
Established that self-management interventions including action plans reduce hospital admissions and length of stay in COPD. Provided evidence base for digital self-management approaches as scalable alternatives to in-person programs.
[2]

Janjua S, Banchoff E, Threapleton CJ, et al.

Cochrane Database Syst Rev 2021;4:CD013246
Systematic Review Digital Health
Identified lack of consistency in digital COPD intervention studies: small samples, heterogeneous designs, limited follow-up, and inconsistent endpoints. Highlighted need for studies like RECEIVER with longer follow-up and clear utilization metrics.
[3]

North M, Bourne S, Green B, et al.

NPJ Digit Med 2020;3:145
RCT Digital Health
The RESCUE trial demonstrated feasibility of e-health supported care post-exacerbation. Showed digital tools can support recovery but highlighted challenges in sustained engagement, which RECEIVER addressed through co-design and integration with routine care.
[4]

Collins PF, Stratton RJ, Kurukulaaratchy RJ, Elia M.

Int J Chron Obstruct Pulmon Dis 2018;13:1289–1296
Observational Health Inequity
Demonstrated that deprivation independently increases COPD hospitalization and mortality risk. Made RECEIVER’s finding of equivalent utilization across SIMD quintiles particularly significant for digital health equity.
[5]

Bucknall CE, Miller G, Lloyd SM, et al.

BMJ 2012;344:e1060
RCT Self-Management
The Glasgow Supported Self-management Trial (GSuST) showed that structured self-management reduces admissions in severe COPD. RECEIVER outcomes align with GSuST findings, suggesting digital tools can support similar benefits when properly designed.
[6]

Alqahtani JS, Oyelade T, Aldhahir AM, et al.

PLoS One 2021;16(8):e0255659
Meta-Analysis COVID-19
Systematic review showing reduction in COPD hospitalizations during COVID-19 due to decreased respiratory infection transmission. Justified RECEIVER’s use of matched controls from same time period to account for pandemic effects on baseline admission rates.
Question 1 of 5
What percentage of RECEIVER participants met the definition of “sustained users” by completing at least one CAT entry per week on ≥50% of follow-up weeks?
Correct! 77% of participants (64/83) were sustained users, completing at least one CAT entry per week on ≥50% of their follow-up weeks. This high rate persisted across mean follow-up of 78 weeks, demonstrating exceptional long-term engagement.
Not quite. While 58% resided in SIMD quintile 1 areas, the sustained user rate was actually 77% (64/83 participants). This high engagement rate was consistent across socioeconomic strata, addressing digital health equity concerns.
Question 2 of 5
How were the 415 control cohort participants matched to the 83 RECEIVER participants?
Correct! The control cohort was identified from NHS GG&C Safe Haven data using strict matching criteria: same sex, closest age match (top 5), COPD/respiratory admission within 7 days of the RECEIVER participant’s onboarding date, alive at that date, and not using the digital service. This 5:1 matching (415 controls) mitigated biases from incomplete control data.
Not quite. While demographic and clinical similarity would be ideal, Safe Haven data availability limited matching to sex, age, admission timing (±7 days), and service non-use. Five controls per participant compensated for incomplete granular clinical data like lung function and smoking status.
Question 3 of 5
What was the median time to death or COPD/respiratory-related admission in the RECEIVER cohort compared to controls?
Correct! RECEIVER participants had significantly longer median time to first admission or death: 335 days versus 155 days in controls (p=0.047, unadjusted HR 0.740). This 180-day difference represents meaningful clinical benefit and was the study’s only statistically significant survival metric.
Not quite. The 335 vs 155 days comparison was statistically significant (p=0.047) with RECEIVER participants showing longer event-free survival. While time to first admission alone (400 vs 255 days) and mortality (16.9% vs 24.1%) trended favorably, they didn’t reach significance.
Question 4 of 5
Why did the study include both RECEIVER participants AND a matched control cohort from routine clinical data?
Correct! The control cohort addressed a critical confound: COVID-19 protective measures reduced community respiratory infection transmission, leading to decreased COPD exacerbation rates system-wide. Time-period matched controls from the same health board established baseline COVID-19 effects, allowing RECEIVER outcomes to be interpreted against appropriate context rather than pre-pandemic historical data.
Not quite. While recruitment did stop early (March 2020), the control cohort’s primary purpose was methodological: accounting for the documented reduction in COPD admissions during COVID-19 restrictions. Without contemporary controls, improved RECEIVER outcomes could have been misattributed to pandemic effects rather than the intervention.
Question 5 of 5
What was the mean reduction in annual occupied bed days for RECEIVER participants compared to controls?
Correct! RECEIVER participants reduced annual occupied bed days by mean 8.12 days versus 3.38 days in controls (Wilcoxon effect size 0.535). This 4.74-day differential represents substantial healthcare utilization reduction with implications for system capacity, costs, and environmental impact beyond individual patient benefit.
Not quite. Both cohorts reduced OBDs post-index (likely COVID-19 protective measure effects), but RECEIVER reduction was substantially larger: 8.12 days versus 3.38 days in controls. The baseline pre-index OBDs were similar (15.19 vs 15.90), confirming successful matching on disease severity.
— / 5 Quiz Score
Core Thesis
Co-designed digital COPD support services can achieve sustained high engagement across socioeconomic strata when integrated with routine care rather than replacing it. The RECEIVER trial demonstrated that this approach produces measurable clinical benefit: prolonged event-free survival, reduced hospital burden, and maintained quality of life despite progressive disease.
  • 📱

    Digital Health Equity is Achievable Through Design

    Equivalent utilization across all SIMD quintiles directly challenges assumptions about digital exclusion in deprived communities. When tools are co-designed with end users, prioritize usability over feature complexity, and support multiple device types (smartphone/tablet/desktop), socioeconomic status does not predict engagement. Only 41 of 283 screened lacked technology access — lower than anticipated and improving with rising internet adoption in older adults.

  • 💡

    Sustained Engagement Requires Integration, Not Replacement

    Unlike many digital health pilots that attempt to replace existing workflows, Lenus COPD augmented routine care: symptom data reviewed during scheduled appointments or patient-initiated contact, not via continuous surveillance. This reduced clinician burden while maintaining utility. The messaging facility enabled asynchronous communication, and 24 of 39 participants who paused usage subsequently re-engaged — suggesting flexibility increases long-term viability.

  • 🏥

    Clinical Benefits Extended Beyond Admissions to System-Level Impact

    The 8.12-day mean reduction in annual occupied bed days represents more than individual patient benefit. At population scale, this creates healthcare capacity, reduces costs (hospitalization is COPD’s primary expense driver), and lowers environmental impact (NHS emissions reduction targets). The 335 vs 155 day median time to admission/death (p=0.047, HR 0.740) provided statistically significant evidence of improved outcomes.

  • ⚙️

    Implementation Science Design Enabled Real-World Validity

    The hybrid implementation-effectiveness framework allowed RECEIVER to evaluate both “does it work?” (clinical outcomes) and “can we deploy it?” (utilization, workflow integration) simultaneously. Using contemporary matched controls from Safe Haven data accounted for COVID-19’s impact on COPD exacerbation rates, strengthening causal inference despite the observational design. This pragmatic approach increases generalizability to routine care settings.

  • 📊

    Granular PRO Data Creates Infrastructure for Future Innovation

    Beyond immediate clinical utility, daily CAT entries, weekly dyspnoea scores, and four-weekly quality-of-life measurements generate rich longitudinal datasets. These enable machine learning model development for exacerbation prediction, personalized intervention timing (JITAIs), and digital biomarker validation. The infrastructure also supports integration of emerging technologies: smart inhalers, remotely-monitored NIV, and wearable physiology sensors.

  • 🎯

    Co-Design Drove Usability and Adoption

    System Usability Scale score of 85/100 directly resulted from iterative patient and clinician co-design incorporating semi-structured interviews. This contrasts with technology-first approaches where features precede needs assessment. The sustained 79.8% mean weekly completion rate and average 4.0 daily CAT entries suggest the tool solved real problems users experienced, rather than imposing externally-defined workflows.

  • 🌍

    Context Matters: COVID-19 as Natural Experiment

    Recruitment cessation in March 2020 was a limitation that became a methodological strength. The pandemic’s reduction in community respiratory infection transmission decreased baseline COPD exacerbation rates system-wide. By including time-period matched controls experiencing identical environmental conditions, the study isolated intervention effects from pandemic effects. This reinforces the importance of contemporary rather than historical comparators in pragmatic trials.

© KMS / GIVEMEA
Created as a personal study aid in accordance with Art. 19 URG (Swiss Copyright Act — private use exception).
Incorporates summarised content from academic sources for non-commercial educational purposes only.
Not for redistribution, reproduction, or commercial use.
⚖ The original structure, design, and framing of this material constitute original intellectual work protected under Swiss law. Unauthorised copying or redistribution may constitute infringement under the URG and applicable international copyright conventions.

Similar Posts

Leave a Reply